Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion 131 to meet its primary endpoints, and future directions for atezolizumab research. The late-breaking abstract ‘IMpassion130: final OS analysis from the pivotal Phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer’ (LBA16) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.
- Could you give us a brief overview of the IMpassion 130 study and its efficacy and safety findings? (0:29)
- What have we learned from the final overall survival analysis of this study? (5:02)
- What are your thoughts on the failure of IMpassion 131 to meet its primary endpoints? (6:00)
- What are the implications of the findings of IMpassion 130 and 131 for future clinical practice? (8:33)
- How can the efficacy of atezolizumab be improved in this hard-to-treat patient population, and what future studies are planned? (10:05)
Speaker Disclosures: Prof Leisha A Emens would like to declare the following: consulting/advisory board/honoraria – honoraria to self; AbbVie – honoraria; Amgen – honoraria; AstraZeneca – honoraria, travel/accommodation/expenses; Bayer – honoraria, travel/accommodation/expenses; Bristol Meyers Squibb – travel/accommodation/expenses; Celgene – honoraria; Chugai – honoraria; CytomX – no compensation; eTHeRNA – no compensation; Genentech – travel/accommodation/expenses; Gritstone – honoraria; Medimmune – honoraria; Molecuvax (potential for stock in future); Macrogenics – honoraria, travel/accommodation/expenses; Novartis – travel/accommodation/expenses; Peregrine – honoraria; Replimune – honoraria, travel/accommodation/expenses; Roche – travel/accommodation/expenses; Shionogi – advisory board, honoraria; Silverback – no compensation; Syndax – honoraria; Vaccinex – honoraria, travel/accommodation/expenses.
Support: Interview and filming supported by Touch Medical Media Ltd. The IMpassion trial was sponsored by F. Hoffmann-La Roche, Ltd.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Immunotherapy
Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]
Michael Atkins: Safe and Effective Use of Immune Checkpoint Inhibitors in Patients with Cancer
Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors. 1. Having a rational approach to stopping therapy (00:50-02:20) 2. An improved understanding of toxicity and response (02:20-04:25) 3. The role of combining and sequencing immunotherapy with standard […]
Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy
touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer. Questions 1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51) 2. What are […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!